Innate Pharma (IPHA) Cash from Financing Activities (2019 - 2024)
Innate Pharma posted quarterly Cash from Financing Activities of -$6.4 million for Q4 2024, down 203.51% year-on-year from $6.2 million in Q1 2024, and down 203.51% on a QoQ basis from -$2.1 million in Q4 2023.
Innate Pharma (IPHA) has 6 years of Cash from Financing Activities data on file, last reported at -$6.4 million in Q4 2024.
- For the quarter ending Q4 2024, Cash from Financing Activities fell 203.51% year-over-year to -$6.4 million; the trailing twelve-month figure through Dec 2024 stood at -$9.9 million (down 55.5% YoY), and the FY2025 full-year result was $7.1 million, up 210.06% from the prior year.
- Cash from Financing Activities for Q4 2024 stood at -$6.4 million, down from -$2.1 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at -$1.0 million in Q2 2022 and bottomed at -$6.4 million in Q4 2024.
- The 5-year median for Cash from Financing Activities is -$1.4 million (2020), against an average of -$2.1 million.
- The widest annual swing landed in 2022, when Cash from Financing Activities surged 30.62%; it then tumbled 203.51% in 2024.
- A 5-year view of Cash from Financing Activities shows it stood at -$1.4 million in 2020, then fell by 5.21% to -$1.5 million in 2021, then decreased by 26.32% to -$1.9 million in 2022, then retreated by 13.42% to -$2.1 million in 2023, then sank by 203.51% to -$6.4 million in 2024.
- The last three Cash from Financing Activities figures came in at -$6.4 million (Q4 2024), -$2.1 million (Q4 2023), and -$1.4 million (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 7.00 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | -600,000.00 |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | 53,000.00 |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | -538.80 Mn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | -802.20 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 15.71 Mn |
| 10 | Innate Pharma | 199.64 Mn | 199.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -6.42 Mn |
| Dec 31, 2024 | -6.42 Mn |
| Dec 31, 2023 | -2.12 Mn |
| Dec 31, 2023 | -2.12 Mn |
| Jun 30, 2023 | -1.36 Mn |
| Jun 30, 2023 | -1.36 Mn |
| Dec 31, 2022 | -1.87 Mn |
| Dec 31, 2022 | -1.87 Mn |
| Jun 30, 2022 | -1.02 Mn |
| Jun 30, 2022 | -1.02 Mn |
| Jun 30, 2021 | -1.48 Mn |
| Jun 30, 2021 | -1.48 Mn |
| Dec 31, 2020 | -1.40 Mn |
| Dec 31, 2020 | -1.40 Mn |
| Jun 30, 2020 | -1.32 Mn |
| Jun 30, 2020 | -1.32 Mn |
| Jun 30, 2019 | -867,449.38 |
| Jun 30, 2019 | -867,449.38 |